Fig. 1From: Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry studyPatients with hematologic malignancies who were reported as having COVID-19 and who were included in the present analysis. Reporting hospitals included 22 of the 26 SERMAS regional health service centers (8/8 designated high complexity level hospitals; 10/12 intermediate complexity level; 4/6 low complexity level), and 5 of the 6 private centersBack to article page